Trial Summary
What is the purpose of this trial?
Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D).
Eligibility Criteria
Adults over 18 with Type 2 diabetes for at least 6 months, who are fluent in English or Spanish, can text, and have a history of high HbA1c levels. Excluded are those planning to leave their clinic soon, unable to consent, with significant mental health or substance issues, pregnant women, participants in other diabetes studies, or patients with severe kidney problems.Inclusion Criteria
I have been diagnosed with type 2 diabetes for at least 6 months.
PCP Group: Fulltime primary care provider (MD/DO, NP) practicing at the participating family health centers or faculty group practices and provide care to at least five patients with a diagnosis of T2D
My type 2 diabetes is uncontrolled with HbA1c over 7% in the last year.
See 3 more
Exclusion Criteria
You have a serious mental health condition or a history of substance abuse.
Patient Group: Plan to discontinue care at the clinic within the next 12 months
Patient Group: Are pregnant or planning to become pregnant within 12 months
See 3 more
Treatment Details
Interventions
- iMatter2 (Other)
Trial OverviewThe trial is testing iMatter2—a mobile tool for reporting patient outcomes—against usual care to see if it better reduces long-term blood sugar levels (HbA1c) in people with Type 2 diabetes after one year.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: iMatter2Experimental Treatment1 Intervention
All the patients within a primary care provider (PCP) randomized to the intervention will receive iMatter2.
Group II: Usual Care (UC)Active Control1 Intervention
All patients within PCPs randomized to UC will receive standard Type 2 diabetes (T2D) care by their PCP.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
NYU Langone HealthNew York, NY
Loading ...
Who Is Running the Clinical Trial?
NYU Langone HealthLead Sponsor
Agency for Healthcare Research and Quality (AHRQ)Collaborator